We will have limited operations from 15:00 Tuesday 24 December 2024 (AEDT) until Thursday 2 January 2025. Find out how to contact us during the holiday period.
Results for
"[search-keyword]"
Sponsor content
44 result(s) found, displaying 1 to 10
-
Prescription medicine registrationActive ingredients: brexpiprazole.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VYEPTI eptinezumab 100 mg/mL concentrated injection single use vial.
-
Australian Public Assessment Report (AusPAR)New AusPAR for Vyepti (eptinezumab) for the preventive treatment of migraine in adults.
-
Prescription medicine registrationActive ingredients: eptinezumab.
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Brexpiprazole
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
Section 14, TGO91 consentProduct(s) approved for Supply with noncompliant labelling.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ABILIFY MAINTENA aripiprazole (as monohydrate) 300 mg powder and solvent for prolonged release suspension for injection pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for ABILIFY MAINTENA aripiprazole (as monohydrate) 400 mg powder and solvent for prolonged release suspension for injection pre-filled syringe.